By emphasizing the expanding therapeutic scope of GLP-1 beyond traditional metabolic targets, we elucidate the current evidence and potential mechanisms of GLP-1R agonists in neurological conditions other than PD and AD. This evidence concerns the gene GLP1R and Alzheimer disease.